MRK
Merck & Co., Inc.
Healthcare · Drug Manufacturers - General · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- Merck's perfect profitability sub-score of 20.0 out of 20 is a primary anchor for the 62.9 total, reflecting that the company's margin and return metrics from its FY2025 10-K are at the highest tier the model recognizes.
- The financial health sub-score of 16.0 out of 20 indicates that Merck's leverage ratio, interest coverage, and balance sheet scale fall in the upper portion of the model's range, contributing meaningful points to the overall score.
- The dividend sub-score of 12.5 out of 20 adds further support to the composite score, as Merck's FCF payout ratio and dividend-per-share growth track record meet multiple favorable criteria in the scoring framework.
Why Not Higher
- The growth and momentum sub-scores each register only 10.0 out of 20, together contributing 20 points out of a possible 40 from those two dimensions alone, which is the single largest factor preventing the overall score from reaching the upper tier of the model's range.
- The theme sub-score of 0.0 out of 20 means Merck receives no credit for macro-theme alignment, leaving 20 potential points entirely uncaptured and effectively capping the composite score regardless of how strong the other dimensions are.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Merck & Co., Inc. is one of the world's largest pharmaceutical companies, headquartered in Rahway, New Jersey, with a broad portfolio spanning oncology, vaccines, infectious disease, and animal health. Its flagship product, Keytruda (pembrolizumab), has become one of the best-selling cancer therapies globally, and the company's pipeline and commercial execution have made it a central name in large-cap healthcare. Against this backdrop, the model assigned Merck a score of 62.9/100 using FY2025 10-K data mapped across all ten core metrics, reflecting a company with genuine strengths in profitability and dividends but notable pressures on growth momentum and no identified macro-theme exposure in the current scoring framework. The profitability sub-score of 20.0 out of 20 signals that Merck's net margins, operating margins, and return on assets are among the strongest observable in its filing data, while the dividend sub-score of 12.5 reflects solid free-cash-flow coverage and a consistent dividend-per-share growth track record. However, the growth sub-score of 10.0 and momentum sub-score of 10.0 suggest that year-over-year revenue, net income, and EPS growth rates, as well as sequential quarterly improvements, are mixed or decelerating rather than accelerating — a meaningful drag on an otherwise strong fundamental profile. The core research tradeoff is between Merck's exceptional earnings quality and dividend sustainability on one hand, and its near-term growth deceleration and a theme score of zero on the other.
Plain English
Merck is a giant pharmaceutical company that makes cancer drugs, vaccines, and other medicines sold worldwide. A model score of 62.9 out of 100 means it scores very well on profitability and dividends — the company consistently generates strong earnings and returns cash to shareholders — but it scores lower on growth and momentum, meaning the pace of expansion appears to be slowing based on its most recent annual filing. The Medium risk rating reflects that while Merck is a well-established business with solid financials, it faces real headwinds around growth sustainability that researchers should weigh carefully.
Bull Case vs. Bear Case
Bull Case
- Merck's profitability sub-score reached the maximum 20.0 out of 20, indicating that net margins, operating margins, and return on assets derived from the FY2025 10-K are at the top of the model's range, reflecting exceptional earnings quality relative to peers.
- The dividend sub-score of 12.5 out of 20 reflects a combination of consistent dividend-per-share growth, a manageable free-cash-flow payout ratio, and strong FCF coverage, positioning Merck as a credible research candidate for dividend income-focused profiles.
- With all ten core metrics successfully mapped from EDGAR filings and a confidence score of 10.0 out of 10, the model's assessment of Merck rests on a complete and high-integrity data set, lending additional weight to the bullish elements of the profile.
Bear Case
- The growth sub-score of 10.0 out of 20 signals that year-over-year improvements in revenue, net income, and earnings per share as reported in the FY2025 10-K are underwhelming relative to the model's full range, raising questions about Merck's near-term top-line trajectory.
- The momentum sub-score of 10.0 out of 20 indicates that sequential quarterly progress in revenue, earnings, and margins is not showing meaningful acceleration, suggesting the strong profitability profile may not be translating into improving fundamental trends.
- A theme score of 0.0 out of 20 means Merck's business model, as evaluated in the filing data, did not register exposure to any of the macro themes tracked by the scoring model, which limits its attractiveness for researchers seeking companies aligned with emerging structural growth drivers.
What Could Change the Picture
Bullish Triggers
- A reacceleration in year-over-year revenue and EPS growth in a subsequent annual filing — particularly driven by pipeline approvals or Keytruda label expansions that appear in the 10-K's product revenue disclosures — would likely push the growth sub-score meaningfully above 10.0.
- If future EDGAR filings demonstrate that Merck's business now intersects with macro themes tracked by the scoring model, such as AI-driven drug discovery, biosimilars, or global vaccine infrastructure, the theme sub-score could move from 0.0 and significantly lift the composite score.
Bearish Triggers
- A deterioration in free cash flow coverage of dividends, as evidenced in a future 10-K, would directly pressure the dividend sub-score of 12.5 and undermine the primary reason Merck rates well for dividend income-focused research profiles.
- Any meaningful increase in the leverage ratio or reduction in interest coverage reported in a future filing would compress the current financial health sub-score of 16.0, weakening one of the key structural supports for the 62.9 composite score.
Red Flags
- The combination of a growth sub-score of 10.0 and a momentum sub-score of 10.0 from the same FY2025 filing cycle suggests that both annual and sequential fundamental trends are simultaneously weak, which may indicate structural rather than temporary deceleration in Merck's core business performance.
Risk Profile
Medium RiskMerck's Medium risk rating reflects a company with strong profitability and balance sheet metrics that nonetheless faces demonstrable uncertainty around growth sustainability and sequential momentum, as captured in the FY2025 10-K data, meaning the fundamental outlook is stable but not without meaningful downside scenarios tied to pipeline execution and revenue concentration. The absence of macro-theme exposure in the model further reinforces that Merck's risk profile is tied primarily to its existing commercial portfolio rather than to higher-growth structural tailwinds.
Key Catalysts to Watch
The key factors to monitor in future EDGAR filings include whether Merck can reignite year-over-year revenue and EPS growth — particularly as Keytruda faces evolving patent dynamics — and whether the company's pipeline of new molecular entities and combination therapies begins generating reportable revenue that improves both the growth and momentum sub-scores. Continued strong free cash flow generation relative to dividend payments will also be critical to sustaining the dividend sub-score that anchors Merck's best-fit profile of dividend income at 71.2.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.